Idera Pharmaceuticals, Inc. (IDRA)
Stock analysis · NASDAQ · Healthcare · Biotechnology
Idera Pharmaceuticals, Inc. (IDRA) is a publicly traded company in the Healthcare sector. Latest price: $0.43. Trailing PE -0.06. Sign in to Stocks360 for full DCF valuation, fundamentals, technicals, and AI-driven analysis.
Get full analysis → Short-Term Analysis →Earnings
Proprietary Signals
About Idera Pharmaceuticals, Inc.
Idera Pharmaceuticals, Inc. is a biopharmaceutical company committed to the research, development, and commercialization of medicines addressing rare diseases within the United States. A key offering is Tilsotolimod (IMO-2125), a proprietary synthetic phosphorothioate oligonucleotide. This compound functions as a direct TLR9 agonist, designed to stimulate the immune system to combat solid tumors, specifically targeting head and neck squamous cell carcinoma and colorectal cancer. The firm also holds a strategic collaboration agreement with Bristol-Myers Squibb. Founded in 1989, Idera Pharmaceuticals, Inc. is headquartered in Exton, Pennsylvania.
Valuation
| P/E (TTM) | -0.06× |
|---|---|
| P/S (TTM) | 0.00× |
| P/B | 0.12× |
| PEG | 0.00× |
| P/FCF (TTM) | 0.00× |
| EV / EBITDA | 0.41× |
| EV / Sales | 0.00× |
| Earnings Yield | -1688.11% |
| Free Cash Flow Yield | 0.00% |
Fundamentals
| Enterprise Value | -$11.48M |
|---|---|
| Net Income (TTM) | $0.00 |
| Free Cash Flow (TTM) | -$24.33M |
| Net Debt | -$11.48M |
| Working Capital | -$3.56M |
| Gross Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
| Return on Equity | -113.18% |
| Return on Invested Capital | -27.40% |
Peers
Recent News
- No recent news available.
Related
Browse more tickers: sitemap